PensionDanmark Pensionsforsikringsaktieselskab Has $6.54 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

PensionDanmark Pensionsforsikringsaktieselskab increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.9% during the 2nd quarter, Holdings Channel reports. The fund owned 38,791 shares of the company’s stock after buying an additional 4,131 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Neurocrine Biosciences were worth $6,538,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. AQR Capital Management LLC boosted its position in shares of Neurocrine Biosciences by 18.0% during the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock worth $462,652,000 after purchasing an additional 498,058 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Neurocrine Biosciences by 8.0% during the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock worth $318,665,000 after acquiring an additional 180,100 shares in the last quarter. Geode Capital Management LLC grew its stake in Neurocrine Biosciences by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after acquiring an additional 34,457 shares during the period. Los Angeles Capital Management LLC grew its stake in Neurocrine Biosciences by 7.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock valued at $178,248,000 after acquiring an additional 88,522 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Neurocrine Biosciences by 31.9% in the fourth quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after acquiring an additional 295,470 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 2.2%

Shares of NBIX opened at $163.41 on Friday. The stock has a market capitalization of $16.61 billion, a P/E ratio of 23.96, a P/E/G ratio of 0.58 and a beta of 0.39. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12. The company has a 50 day moving average of $168.49 and a 200-day moving average of $147.45.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Stifel Nicolaus increased their target price on Neurocrine Biosciences from $188.00 to $215.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. BMO Capital Markets lifted their price target on shares of Neurocrine Biosciences from $144.00 to $170.00 and gave the company a “market perform” rating in a research note on Monday, July 13th. TD Cowen upped their price target on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Wells Fargo & Company boosted their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $201.50.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director Kevin Charles Gorman sold 245,088 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total value of $37,824,431.04. Following the completion of the transaction, the director owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. This trade represents a 32.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the transaction, the director owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. This represents a 30.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 395,422 shares of company stock valued at $62,448,693 in the last three months. 4.60% of the stock is currently owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.